Prot #RIV-HU6-2201: Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 for the Treatment of Subjects with Obese Heart Failure with Preserved Eje

Project: Research project

Project Details

Effective start/end date3/6/233/6/26


  • Medpace Clinical Research LLC (Prot #RIV-HU6-2201 // Prot #RIV-HU6-2201)
  • Rivus Pharmaceuticals, Inc. (Prot #RIV-HU6-2201 // Prot #RIV-HU6-2201)